Logo-bi
Original Research

1. Poly(ethylene glycol)-poly(ε-caprolactone)-based micelles for solubilization and tumor-targeted delivery of silibinin
Ashkan Hassankhani Rad ORCID, Farshid Asiaee ORCID, Sevda Jafari ORCID, Ali Shayanfar ORCID, Afsaneh Lavasanifar ORCID, Ommoleila Molavi* ORCID
Bioimpacts. 2020;10(2): 87-95. doi: 10.34172/bi.2020.11
PMCID: PMC7186544     PMID: 32363152     Scopus ID: 85086435091    
Article
PDF
Full Text
XML
Cited By:
20
6
11
Silibinin is a natural and non-toxic compound which has some beneficial effects in cancer treatment. But, poor water solubility of silibinin limits its clinical application. Here, encapsulation of silibinin in the PEG-PCL based micelles increased water solubility of silibinin and enhanced its functional delivery to melanoma cancer cells.
Original Article

2. PCL-based nanoparticles for doxorubicin-ezetimibe co-delivery: A combination therapy for prostate cancer using a drug repurposing strategy
Mina Yousefnezhad, Soodabeh Davaran* ORCID, Mirzaagha Babazadeh, Abolfazl Akbarzadeh, Hamidreza Pazoki-Toroudi
Bioimpacts. 2023;13(3): 241-253. doi: 10.34172/bi.2023.24252
PMCID: PMC10329752     PMID: 37431480     Scopus ID: 85157052599    
Article
PDF
Full Text
XML
Cited By:
10
0
4
Drug repurposing is an effective strategy for identifying and using approved drugs for new therapeutic purposes. We investigated co-delivery of the antitumor drugs, doxorubicin (DOX), and ezetimibe (EZ) as a cholesterol uptake-blocking drug with PCEC on prostate cancer cell line (PC3).
Original Article

3. Development, in vitro, and in vivo assessments of PCL-gelatin-βTCP fibrous scaffolds for cardiac regeneration
Mahnaz Fathi ORCID, Nafiseh Baheiraei* ORCID, Nahid Moradi, Majid Salehi, Sepehr Zamani ORCID, Mehdi Razavi, Hossein Eyni
Bioimpacts. 2025;15: 31096 | Published on: 2025 Aug 17. doi: 10.34172/bi.31096
Article
PDF
XML
Cited By:

As a peer-reviewed international open-access journal, BioImpacts publishes articles on basic and translational aspects of pharmaceutical and biomedical sciences. 
Acceptance rate (2024): 20% 
Publication fee: Free of charge

Indexing/Abstracting Info
PubMed; PubMed Central; Scopus; Science Citation Index Expanded; Google Scholar;   SJR; Essential Science Indicators; Embase; EBSCOhost; CAS: DOAJ: SHERPA/RoMEO
Member of   
Follower of ICMJE
Permission: Creative Commons